Market News Call

Hot Stocks: Celldex Therapeutics, Inc. (NASDAQ:CLDX), NPS Pharmaceuticals, Inc.(NASDAQ:NPSP), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Lakeway, NY — (MARKET NEWS CALL) — 11/22/2013 —, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on NPS Pharmaceuticals, Inc.(NASDAQ:NPSP), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Celldex Therapeutics, Inc. (NASDAQ:CLDX).

NPS Pharmaceuticals, Inc.(NASDAQ:NPSP) shares fell 0.26% to $23.29. The company on Nov. 20 announced that it has been named one of New Jersey’s 50 Fastest Growing Companies of 2013 by NJBIZ, the state’s premier business news publication. “Being recognized as one of the 50 Fastest Growing Companies in New Jersey is a great honor and a testament to our remarkable growth,” said Francois Nader, M.D., president and chief executive officer of NPS Pharmaceuticals. “It’s an exciting time to be a part of the NPS team as we enter our next phase of growth to become a premier global orphan drug company and continue to work hard each day to bring innovative therapies to patients suffering from rare diseases around the world.”

Should Investors Buy NPSP After Yesterday’s Slump? Find Out Here

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares jumped 1.67% to $66.23. The company on Nov. 20 said it is selling its product royalty rights for the hepatitis C treatment Incivo for $152 million to Johnson & Johnson subsidiary Janssen Pharmaceutica. Vertex said that Janssen will make the cash payment in the fourth quarter and then stop paying royalties in 2014. Cambridge, Mass.-based Vertex plans to use the money to bolster its drug development pipeline, including its research into cystic fibrosis.

Can Traders Buy VRTX After The Solid Rally? Get Free Trend Analysis Here

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares increased 5.58% to $26.09. The company on Nov. 11 announced that preliminary data from “ReACT: a Phase 2 Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma”, was published in the 2013 abstract supplement to the journal Neuro-Oncology; abstracts were also published online at Data included in the abstract were as of the time of submission (May 2013) and more comprehensive, updated data from the study will be presented by David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Dana Farber Cancer Center and Associate Professor of Medicine, Harvard Medical School during an oral session on Sunday, November 24 from 10:20 am to 12:00 pm PT at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology in San Francisco, CA.

Should Investors Rush To Buy CLDX After The Solid Rally? Get Special Report Here

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.

Tags: , , , ,

Leave your comment here